If Roche (
$RHHBY) had a drug-development trading card, its stats would look something like this: R&D budget of $9 billion, with 72 development programs, 19 late-stage studies and 12 candidates for near-term approval. Top player in the line-up, at least for now? T-DM1, its on-the-verge-of-approval treatment for
breast cancer.
About US
Contact us
